The Drug Interactions Study of Clopidogrel in vitro

Shuai-bing LIU,Xiao-liang DING,Chen-rong HUANG,Ling XUE,Zi-teng WANG,Li-yan MIAO

DOI: https://doi.org/10.3969/j.issn.1009-881X.2014.01.004

2014-01-01

Abstract:Objective To investigate the effect of CYP2C19 and carboxylesterase 1 substrate that were often used in combination with clopidogrel in clinic and provide some useful information for the rational use of clopidogrel in clinic. Methods Omeprazole, CYP2C19 substrate, was chosen, enalapril, oseltamivir, simvastatin, rosiglitazone and fluoxetine, CES1 substrates were selected, the interactions between clopidogrel and these drugs were explored in vitro using human liver microsomes. The concentrations of clopidogrel inactive and active metabolite in the incubation system were determined by a LC-MS/MS method. Results Omeprazole significantly inhibited the formation of the clopidogrel active metabolite (P<0.05). Simvastatin exhibited varying degrees of inhibition towards the generation of both inactive and active metabolite of clopidogrel, other selected substrates did not affect the production of either inactive or active metabolite of clopidogrel (P>0.05). Conclusion Omeprazole and simvastatin showed different degrees of metabolic inhibition towards clopidogrel. When clopidogrel prescribed in combination with these drugs, the interactions of them should not be ignored in clinic.